Physician profile
John E Bitner
NPI 1134118763
$1,887.51
in general payments reported to CMS, 2019-2025
24 companies · $261 in 2025
The $261 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $175 · 2021: $152 · 2022: $249 · 2023: $413 · 2024: $447 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,120.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $370.61 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $257.97 | 2019-2025 | Mounjaro, Zepbound |
| Mylan Specialty L.P. | $234.43 | 2021-2024 | Yupelri |
| Glaxosmithkline, LLC. | $196.03 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $152.44 | 2023-2024 | Vraylar |
| Axsome Therapeutics, INC. | $92.62 | 2023 | Auvelity |
| Exact Sciences Corporation | $66.26 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $65.25 | 2024-2025 | Repatha, Otezla, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $53.23 | 2022-2025 | Trintellix |
| Novartis Pharmaceuticals Corporation | $49.05 | 2022-2023 | |
| Horizon Therapeutics Plc | $47.78 | 2019-2021 | |
| Pfizer INC. | $43.34 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.88 | 2020-2023 | Ofev |
| Janssen Pharmaceuticals, INC | $35.03 | 2019 | |
| Dexcom, INC. | $33.87 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $21.15 | 2019 | |
| Esperion Therapeutics, INC. | $19.80 | 2020 | |
| Jazz Pharmaceuticals INC. | $19.69 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.04 | 2024 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals Lp | $15.55 | 2024 | Airsupra |
| Galderma Laboratories, L.P. | $15.10 | 2025 | |
| Corcept Therapeutics | $15.05 | 2019 | |
| Amarin Pharma, INC. | $14.87 | 2020 | |
| Merck Sharp & Dohme LLC | $12.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bitner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.